Get the Stockscreener App
8.33
4.14%
-0.36
After Hours:
8.33
Agomab Therapeutics Nv Adr stock is traded at $8.33, with a volume of 91,729.
It is down -4.14% in the last 24 hours and down -31.50% over the past month.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
See More
Previous Close:
$8.69
Open:
$8.56
24h Volume:
91,729
Relative Volume:
0.69
Market Cap:
$410.24M
Revenue:
Net Income/Loss:
P/E Ratio:
-12.39
EPS:
-0.6724
Net Cash Flow:
1W Performance:
-9.65%
1M Performance:
-31.50%
6M Performance:
-21.86%
1Y Performance:
+0.00%
1-Day Range:
$8.15
$8.86
1-Week Range:
$8.15
$9.65
52-Week Range:
$7.97
$17.82
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Name
Agomab Therapeutics Nv Adr
Sector
Industry
Phone
-
Address
-
Compare AGMB vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
8.33 | 410.24M | 0 | 0 | 0 | -0.6724 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-26 | Initiated | Piper Sandler | Overweight |
| Aug-19-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-26 | Initiated | B. Riley Securities | Buy |
| Jun-22-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | JP Morgan | Overweight |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Morgan Stanley | Overweight |
View All
Agomab Therapeutics Nv Adr Stock (AGMB) Latest News
What Does AgomAb (AGMB)'s +5.17% Surge Signal for the Sector? 2026-09-17Key Reversal Day - dars.gov.et
AgomAb Therapeutics Director Marino Garcia Granted 57,482 Stock Options - Kalkine Media
Director at Agomab Therapeutics NV (AGMB) receives 57K stock options - Stock Titan
Agomab Therapeutics (AGMB) awards long-dated stock options to director - Stock Titan
Agomab Shareholders Approve New Board Members and Pre-IPO Warrant Adjustment - TipRanks
ETFs Investing in AgomAb Therapeutics NV ADR Stocks - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS) - The Globe and Mail
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMcClellan Summation - siam.in
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionMomentum Breakout Ideas - dars.gov.et
AgomAb (AGMB) Range: Ends Lower by 2.33% at $13.43 in Latest Trading; Technical View: Price Remains Between $12.76 Support and $14.10 Resistance in the Latest SessionFast Moving Stocks - dars.gov.et
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - theglobeandmail.com
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Volatility & Greeks - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AGMBAgomAb Therapeutics NV ADR Latest SEC Filings - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
AGMB - Finviz
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook - GlobeNewswire Inc.
Agomab Therapeutics Nv Adr Stock (AGMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agomab Therapeutics Nv Adr Stock (AGMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kemula Pierre Thadee Victor | Chief Financial Officer |
Oct 06 '26 |
Buy |
8.59 |
10,000 |
85,940 |
10,000 |
| Knotnerus Tim Jasper | Chief Executive Officer |
Oct 06 '26 |
Buy |
8.70 |
5,000 |
43,500 |
21,823 |
| Epstein David R | Director |
Oct 06 '26 |
Buy |
8.70 |
5,000 |
43,500 |
10,000 |
| Epstein David R | Director |
Oct 05 '26 |
Buy |
8.57 |
5,000 |
42,850 |
5,000 |
| Knotnerus Tim Jasper | Chief Executive Officer |
Oct 05 '26 |
Buy |
8.48 |
6,000 |
50,880 |
16,823 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):